Studies are needed to examine whether TG reduction via antisense APOC3 inhibition translates also to improved liver-related outcomes given the close links between hepatic lipoprotein metabolism and NAFLD (Heeren and Scheja, 2021). The gene discussed is APOC3; the disease is metabolic dysfunction-associated steatotic liver disease.